| A Phase I Study of JSKN021 in Advanced Solid Tumors (NCT07617727) | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | 2026-06-02 |
| JSKN033 Combination Therapy in Subjects With Advanced Cervical Cancer (NCT07497074) | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | 2026-04-01 |
| A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care (NCT07533123) | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | 2026-03-17 |
| A Study of JSKN027 in Patients With Advanced Solid Tumors (NCT07391644) | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | 2026-03-15 |
| JSKN016HC in Patients With Advanced or Metastatic Solid Malignant Tumors (NCT07475559) | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | 2026-03-01 |
| JSKN016 in Combination With D-0502 for Locally Advanced or Metastatic HR-Positive, HER2-Negative Breast Cancer (NCT07336771) | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | 2026-01-01 |
| A Phase II Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics/Pharmacodynamics of JSKN033 in Patients With Advanced Non-Small Cell Lung Cancer (NCT07283198) | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | 2025-12-10 |
| JSKN022 in Subjects With Advanced Malignant Solid Tumors (NCT07292402) | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | 2025-10-23 |
| Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast Cancer (NCT06942234) | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | 2025-06-01 |
| Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC (NCT06868732) | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | 2025-04-02 |
| Evaluation of JSKN016 in the Treatment of Advanced Non-small Cell Lung Cance： a Phase II Clinical Study (NCT06775483) | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | 2025-01-17 |
| JSKN003 in Platinum-Resistant, Relapsed Epithelial Ovarian Cancer (NCT06751485) | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | 2025-01-15 |
| JSKN033 in Chinese Subjects with Advanced Malignant Tumors (NCT06770881) | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | 2025-01-15 |
| To Evaluate the Phase I Clinical Study of JSKN016 in Chinese Patients With Advanced Malignant Solid Tumors (NCT06592417) | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | 2024-04-30 |
| JSKN033 in Patients With Advanced or Metastatic Solid Malignant Tumors (NCT06226766) | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | 2024-01-18 |
| JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects (NCT06079983) | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | 2023-12-01 |
| Safety and Tolerability of JSKN003 in Chinese Subjects With Advanced Solid Tumors (NCT05744427) | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | 2023-03-15 |
| Study of KN046 in Subjects With Advanced Non-Small Cell Lung Cancer (NCT05420220) | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | 2022-07-26 |
| Clinical Study of KN052 in Chinese Subjects With Advanced Solid Tumors (NCT05309512) | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | 2022-05-27 |
| Study of KN026 in Combination With Palbociclib and Fulvestrant in Patients With Advanced Breast Cancer (NCT04778982) | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | 2022-05-25 |
| KN046 in Subjects With Advanced Pancreatic Ductal Adenocarcinoma. (NCT05149326) | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | 2022-01-20 |
| KN046 Plus Lenvatinib in Subject With Advanced Non-Small Cell Lung Cancer in the Failure of Anti-PD-(L)1 Agent (NCT05001724) | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | 2021-10-28 |
| Study of KN026 in Combination With Docetaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer (NCT04881929) | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | 2021-08-09 |
| KN046 Combined With Ningatinib in the Treatment of Advanced Hepatocellular Carcinoma (NCT04601610) | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | 2021-06-07 |
| Study of KN026 Combined With KN046 in Patients With Locally Advanced HER2-positive Solid Tumors (NCT04521179) | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | 2020-12-07 |
| KN046 (a Humanized PD-L1/CTLA4 Bispecific Single Domain Fc Fusion Protein Antibody) in Subjects With Thymic Carcinoma (NCT04469725) | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | 2020-12-02 |
| Study of KN026 Monotherapy or Combination Therapy in Patients With Metastatic Breast Cancer (NCT04165993) | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | 2019-12-31 |
| Efficacy and Safety Study of KN019 in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate (NCT04038970) | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | 2019-11-08 |
| Study of KN046 With Chemotherapy in First Line Advanced NSCLC (NCT04054531) | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | 2019-09-04 |
| KN046 in Subjects With Late Stage Esophageal Squamous Cell Carcinoma (NCT03925870) | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | 2019-06-21 |
| KN026 in Patients With HER2 Expressing Breast Cancer and Gastric Cancer (NCT03847168) | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | 2019-06-18 |
| KN026 in Patients With HER2 Expressing Gastric/Gastroesophageal Junction Cancer (NCT03925974) | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | 2019-06-17 |
| A Study of KN046 in Subjects With Locally Advanced or Metastatic Triple-negative Breast Cancer (NCT03872791) | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | 2019-05-30 |
| KN046 in Patients With Advanced Non-small Cell Lung Cancer (NCT03838848) | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | 2019-05-05 |
| KN046 in Subjects With Advanced Solid Tumors and Lymphoma (NCT03733951) | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | 2018-12-18 |
| Trial of KN026 in Patients With HER2-positive Advanced Malignant Breast Cancer and Gastric Cancer (NCT03619681) | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | 2018-09-17 |